Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MGNX
SELLMacroGenics, Inc. · Healthcare · United States · $235M · Avg Vol: $5M/d
COMPANY DESCRIPTION
MacroGenics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative antibody-based therapeutics for cancer and other serious diseases. The company utilizes proprietary DART and TRIDENT platforms to create novel bispecific antibodies with enhanced therapeutic potential. MacroGenics aims to address unmet medical needs through its pipeline of differentiated immuno-oncology and autoimmune drug candidates.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 150.0M | 58.7M | 150.0M | 149.5M | -0.1% | 157.1M | 164.4M | 94.3M | -20.6% |
| EPS | -3.37 | -1.95 | -0.15 | -1.07 | -1.18 | — | -1.07 | — | — | — |
| Shares | — | 61.7M | 62.1M | 62.8M | 63.3M | +2.6% | 63.6M | — | — | — |
| Debt | — | 34.8M | 34.0M | 37.5M | 36.8M | 1.8% | 36.5M | — | — | — |
| Equity | — | 142.0M | 152.6M | 116.1M | 55.6M | -26.8% | — | — | — | — |
| Op CF | — | -87.0M | -78.2M | -68.4M | -81.0M | — | -70.0M | — | — | — |
| Inv CF | — | 70.7M | -80.1M | 149.3M | -114.1M | — | — | — | — | — |
| Fin CF | — | 1.7M | 150.4M | 1.0M | 69.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MGNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MGNX | MacroGenics, Inc.(you) | $235M | 25 | SELL |
| OBIO | Orchestra BioMed Holdings, Inc. | $224M | 21 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 28 | SELL |
| CHRS | Coherus Oncology, Inc. | $217M | 20 | STRONG SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 23 | SELL |
| ACOG | Alpha Cognition Inc. Common Stock | $172M | 26 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 27 | SELL |
| IMRX | Immuneering Corporation | $279M | 21 | SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%